PUBLISHER: Grand View Research | PRODUCT CODE: 1701388
PUBLISHER: Grand View Research | PRODUCT CODE: 1701388
The Europe veterinary 3D printing market size is anticipated to reach USD 73.9 million by 2030, registering a CAGR of 10.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. One of the most dynamic emerging factors affecting the market is the emerging usage of 3D printing in developing veterinary drugs. Although still in the research stage, the application of this technology is being actively studied by many researchers worldwide.
According to an article in Pharma Excipients, 3D printing is being explored to create tailored veterinary drugs, addressing the limitations of traditional one-size-fits-all medications for animals. A joint-collaboration between researchers from around the globe, a research study is focusing on developing a once-daily, dual-release tablet for cats and dogs using semi-solid extrusion (SSE) 3D printing, specifically for Metoclopramide (MCP), a common anti-nausea drug. The dual-release system aims to provide both rapid onset and sustained action, reducing the frequency of administration needed due to MCP's short half-life. They successfully created different-sized tablets with tailored doses, demonstrating a strong correlation between the design and drug amount. These tablets contained cellulosic polymers to control drug release, with dissolution studies showing the impact of polymer combinations and tablet surface area on release profiles.
SSE 3D printing allows for precise dosing and customization of release profiles by altering tablet structures and geometries. The technology is suitable for thermo-sensitive ingredients and minimizes contamination risk compared to traditional methods. Including liver powder in the immediate-release formulation enhances palatability, making the tablets more pet-friendly. This approach offers the potential to revolutionize veterinary medicine by providing customized treatments, improving patient compliance, and optimizing treatment outcomes. The study highlights the practical use of SSE 3D printing in developing precise and pet-friendly tailored tablets, offering enhanced treatment options for small animals close to the point of care.
The use of 3D printing in veterinary medicine has the potential to enable precision in drug formulations and address the unique needs of each animal, overcoming the limitations of standardized medications. It has the potential to provide on-demand production of customized dosages close to the point of care, improving treatment accuracy and reducing preparation errors. Integrating innovative drug delivery systems like dual-release tablets can optimize therapeutic outcomes while minimizing dosing frequency. 3D printing can revolutionize veterinary pharmacology by providing flexible, efficient, and patient-specific solutions.